Rheumatoid arthritis is an autoimmune disease characterized by the formation of pannus, bone destruction, and joint deformation due to various immune cell activities in the joints and hyperproliferation of synovial cells.

Early stage RA patients use single DMARD treatment with MTX. After 3 months of treatment, moderate to severe patients require biologics as an add-on therapy.

A new target drug is needed due to the high recurrence rate and non-responsiveness to the existing treatment.

Considering RA’s pathogenesis, to treat patients more precisely and accurately, a theranostic target that can act as a biomarker is strongly in need.